Moderna (MRNA) shares are surging Thursday after the company announced positive mid-stage trial data showing its experimental cancer vaccine, used in combination with Merck's (MRK) immunotherapy Keytruda, cut the risk of death or relapse by nearly half in patients with advanced melanoma skin cancer after three years.
Moderna CEO Stéphane Bancel joined Yahoo Finance's health reporter Anjalee Khemlani to discuss the results. "We are so happy for patients," Bancel said, noting the data shows roughly 50% survival rates, meaning 1 in 2 treated patients in the trial were able to live without disease relapse.
Bancel also highlighted other vaccines in Moderna's pipeline, including for RSV (Respiratory Syncytial Virus). Bancel expressed confidence in their late-stage RSV candidate will resonate with doctors and pharmacists as it requires only 4 preparation steps, unlike the only approved option which requires 9 complex steps to deliver. With overburdened healthcare workers, Bancel says Moderna aims "to be part of the solution" enabling easier administration.
#vaccine #youtube #stockmarket
About Yahoo Finance:
Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage your financial life.
- Get the latest news and data at finance.yahoo.com
- Download the Yahoo Finance app on Apple (apple.co/3Rten0R) or Android (bit.ly/3t8UnXO)
- Follow Yahoo Finance on social:
X: / yahoofinance
Instagram: yahoofinanc...
TikTok: www.tiktok.com/@yahoofinance?...
Facebook: / yahoofinance
LinkedIn: / yahoo-finance